EU approves Novartis drug for AML with mutation | Opdivo gains UK nod for lung cancer | Guidance on human factors, usability engineering issued by MHRA
September 21, 2017
DIA Global SmartBrief
News on diagnostic and therapeutic innovations and regulatory science
SIGN UP ⋅   FORWARD
Top Story
EU approves Novartis drug for AML with mutation
EU approves Novartis drug for AML with mutation
(Sebastien Bozon/Getty Images)
Novartis received EU approval for Rydapt to treat acute myeloid leukemia with the FLT3 genetic mutation. The drug, already approved in the US, also gained approval for three kinds of advanced systemic mastocytosis.
Reuters (9/20) 
LinkedIn Twitter Facebook Google+ Email
 
Europe
Opdivo gains UK nod for lung cancer
The UK's National Institute for Health and Care Excellence reached a managed access deal with Bristol-Myers Squibb, recommending the company's Opdivo as a second-line treatment for lung cancer.
PharmaPhorum (U.K.) (9/20) 
LinkedIn Twitter Facebook Google+ Email
Guidance on human factors, usability engineering issued by MHRA
A guidance was released by the UK's Medicines and Healthcare products Regulatory Agency to guide medical device makers and notified bodies on human factors and usability engineering. The document includes an overview of device standards and regulations, looks at different usability engineering strategies, details safety considerations and principles that improve use of the device, and includes tables comparing the new rules with the previous ones.
Regulatory Focus (9/19) 
LinkedIn Twitter Facebook Google+ Email
UK firms plan cancer antibody conjugate development
UK drugmakers IONTAS and Glythera are collaborating on the development of antibody drug conjugates to treat difficult cancers. The technology enables monoclonal antibodies to deliver treatment inside targeted cells, improving efficacy while sparing healthy tissue.
PharmaTimes (U.K.) (9/20) 
LinkedIn Twitter Facebook Google+ Email
Asia Pacific
Australia tackles childhood cancer
Australia is launching a nationwide effort called the Zero Childhood Cancer initiative to diagnose and offer personalized treatment of childhood cancers. A clinical trial is projected to enroll more than 400 children in the next three years as physicians and scientists collaborate on research and treatment.
BioSpectrum Asia (9/20) 
LinkedIn Twitter Facebook Google+ Email
Adult ADHD drug promising in trial
In Japanese clinical trials, Shire's Intuniv, or guanfacine hydrochloride, for adult attention-deficit/hyperactivity disorder met its primary endpoint. The selective alpha-2A adrenergic receptor agonist performed better than placebo in the change from baseline on an ADHD rating scale.
PharmaTimes (U.K.) (9/20) 
LinkedIn Twitter Facebook Google+ Email
North America
Regulatory approval doesn't mean biosimilars are available
Only three of the seven FDA-approved biosimilar drugs are available for sale in the US. The others are the subject of patent disputes that may block their sale for years.
Bloomberg (9/18) 
LinkedIn Twitter Facebook Google+ Email
Other News
Global
WHO urges greater effort on antibiotic development
WHO urges greater effort on antibiotic development
(Joe Raedle/Getty Images)
The WHO in a new report says not enough antibacterial drugs are under development to meet the threat of drug-resistant infections, noting that only eight of 51 in development can be termed novel treatments. "There is an urgent need for more investment in research and development for antibiotic-resistant infections including TB," said WHO Director-General Tedros Adhanom Ghebreyesus, who added that if the need isn't met, "we will be forced back to a time when people feared common infections and risked their lives from minor surgery."
The Economic Times (India) (9/20) 
LinkedIn Twitter Facebook Google+ Email
 
DIA News
If you have a biologic, this concerns you
The FDA's final guidance on the naming of biologics (originator and biosimilar), issued this year, is in the implementation process and will have an impact on manufacturers, supply chain, end users and safety systems. All stakeholders will need systematic approaches to ensure adherence -- both prospectively and retrospectively. How will these changes affect your systems and products? What will be your next steps? Download the Biosimilars Navigation Guide and get up to speed on the latest scientific and regulatory topics related to biosimilars.
LinkedIn Twitter Facebook Google+ Email
Upcoming DIA events
LinkedIn Twitter Facebook Google+ Email
Learn more about DIA:
About DIA | Meetings & Trainings | News & Publications | Membership
  
  
Going to bed at night saying we've done something wonderful ... that's what matters to me.
Steve Jobs,
entrepreneur
LinkedIn Twitter Facebook Google+ Email
  
  
Sign Up
SmartBrief offers 200+ newsletters
Advertise
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Advertising  -  Wynn Hansen
P: 202.470.1149
Editor  -  Lisa Gough
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2017 SmartBrief, Inc.®
Privacy policy |  Legal Information